Institute of Bioinformatics
About the Institute
The Institute for Bioinformatics was established in 2010 as the latest member of the Biocenter at the Medical University of Innsbruck and it is dedicated to supporting basic research and teaching in bioinformatics and computational biology. The Institute for Bioinformatics is well equipped both for data processing and management as well as for computational analysis of a broad range of data types, including next-generation sequencing data, proteomics and metabolomics data, and image analysis. It has a state-of-the-art computational infrastructure, which is dedicated to bioinformatics analysis. A number of analytical pipelines, databases and software tools developed by the laboratory and others are installed and continuously maintained.
The research of the Institute of Bioinformatics focuses on cancer immunology. Our aim is to decipher tumour-immune cell interaction by means of a combined computational-experimental approach. We specifically look at the question of how the immune system shapes the mutation spectrum of the tumour, both during progression and after treatment, in patients with colorectal cancer. We use tumour-derived organoids, perturbation experiments and multimodal analysis, including next-generation sequencing, phosphoproteomics and imaging mass cytometry to facilitate precision immuno-oncology.
- Finotello F, Rieder D, Hackl H, Trajanoski Z. Next-generation computational tools for interrogating cancer immunity. Nat Rev Genet. 2019. 20:724-746
- Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, de Miranda N, Trajanoski Z. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019. 11:34
- Efremova M, Rieder D, Klepsch V, Charoentong P, Finotello F, Hackl H, Hermann-Kleiter N, Löwer M, Baier G, Krogsdam AM, Trajanoski Z. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat Commun. 2018. 9:32
- Charoentong P*, Finotello F*, Angelova M*, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017. 18:248-262
- Hackl H, Charoentong P, Finotello F, Trajanoski Z. Computational genomics tools for dissecting tumor-immune cell interactions. Nat Rev Genet. 2016. 17:441-458
- ERC advanced grant EPIC: Enabling immuno-oncology in colorectal cancer (PI: Z. Trajanoski)
- Horizon 2020 INCITE: Immune niches for cancer immunotherapy enhancement (project partner: Z. Trajanoski)
- Horizon 2020 IMI: imSAVAR:Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies (project partner: Z. Trajanoski)
- FWF/DFG: Transregio 241 (DFG) Immune-Epithelial Communication in Inflammatory Bowel Diseases (project partner: Z. Trajanoski)
- FWF doc.funds Cellular Basis of Diseases: Molecular Control of Metabolism and Inflammation (project partner: Z. Trajanoski)
- OeNB Anniversary Fund: Prediction of non-canonical neoantigens for next-generation colorectal cancer immunotherapy (PI: Francesca Finotello)
- OeNB Anniversary Fund: Connection of DNA damage and repair with the immunome in high-grade serous ovarian cancer (PI: Hubert Hackl)